TABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Summary of the most common TRAEs (any grade in ≥30% of patients or grade ≥3 in ≥10% of patients) in the urothelial carcinoma and NSCLC cohorts

尿路上皮癌（urothelial carcinoma）与非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）队列中，最常见的治疗相关不良事件（Treatment-Related Adverse Events, TRAEs，即发生率≥30%的任意级别不良事件，或发生率≥10%的3级及以上不良事件）的汇总情况